NCT04390763
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04390763
Title Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) (daNIS-1)
Acronym daNIS-1
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | GBR | FRA | FIN | ESP | DEU | CZE | CHE | BEL | AUT | AUS

Facility Status City State Zip Country Details
Winship Cancer Institute Atlanta Georgia 30322 United States Details
Sidney Kimmel CCC At JH Baltimore Maryland 21231 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Beth Israel Deaconess Medical Cente Boston Massachusetts 02215 United States Details
Univ of Pittsburgh Cancer Institute Pittsburgh Pennsylvania 15232 United States Details
Novartis Investigative Site Westmead New South Wales 2145 Australia Details
Novartis Investigative Site Melbourne Victoria 3000 Australia Details
Novartis Investigative Site Salzburg 5020 Austria Details
Novartis Investigative Site Vienna A-1090 Austria Details
Novartis Investigative Site Liège 4000 Belgium Details
Novartis Investigative Site Brno Czech Republic 656 53 Czechia Details
Novartis Investigative Site Helsinki FIN-00029 Finland Details
Novartis Investigative Site Paris 75475 France Details
Novartis Investigative Site Toulouse 31054 France Details
Novartis Investigative Site Essen 45147 Germany Details
Novartis Investigative Site Heidelberg 69120 Germany Details
Novartis Investigative Site Ulm 89081 Germany Details
Novartis Investigative Site Milan MI 20132 Italy Details
Novartis Investigative Site Milan MI 20141 Italy Details
Novartis Investigative Site Rozzano MI 20089 Italy Details
Novartis Investigative Site Verona VR 37134 Italy Details
Novartis Investigative Site Singapore 119074 Singapore Details
Novartis Investigative Site Singapore 168583 Singapore Details
Novartis Investigative Site Barcelona Catalonia 08035 Spain Details
Novartis Investigative Site Barcelona Catalonia 08036 Spain Details
Novartis Investigative Site Madrid 28050 Spain Details
Novartis Investigative Site Sankt Gallen 9007 Switzerland Details
Novartis Investigative Site Zurich 8091 Switzerland Details
Novartis Investigative Site Taichung 40447 Taiwan Details
Novartis Investigative Site Taipei 10002 Taiwan Details
Novartis Investigative Site Oxford OX3 7LE United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field